Price
$16.86
Increased by +1.32%
Dollar volume (20D)
43.07 M
ADR%
4.92
Earnings report date
Nov 10, 2025
Shares float
87.02 M
Shares short
27.17 M [31.23%]
Shares outstanding
101.16 M
Market cap
1.68 B
Beta
2.23
Price/earnings
N/A
20D range
15.60 20.14
50D range
15.60 22.80
200D range
13.53 35.25

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies.

The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.

Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Reported date EPSChange YoY EstimateSurprise
Aug 5, 25 -1.00
Increased by +9.91%
-1.11
Increased by +9.91%
May 5, 25 -1.24
Decreased by -2.65%
-1.17
Decreased by -6.04%
Feb 25, 25 -1.09
Decreased by -163.01%
-1.22
Increased by +10.35%
Nov 5, 24 -1.17
Increased by +4.10%
-1.16
Decreased by -0.86%
Aug 6, 24 -1.11
Decreased by -2.78%
-1.13
Increased by +1.77%
May 7, 24 -1.21
Increased by +9.02%
-1.42
Increased by +14.79%
Feb 27, 24 1.73
Increased by +420.37%
-1.01
Increased by +271.29%
Nov 8, 23 -1.22
Increased by +21.79%
-1.36
Increased by +10.29%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 8.47 M
Decreased by -28.08%
-102.29 M
Decreased by -12.34%
Decreased by -1.21 K%
Decreased by -56.22%
Mar 31, 25 7.47 M
Increased by +0.81%
-109.27 M
Decreased by -10.74%
Decreased by -1.46 K%
Decreased by -9.85%
Dec 31, 24 30.07 M
Decreased by -90.49%
-90.35 M
Decreased by -163.27%
Decreased by -300.51%
Decreased by -765.41%
Sep 30, 24 14.27 M
Decreased by -17.01%
-96.67 M
Decreased by -0.60%
Decreased by -677.47%
Decreased by -21.22%
Jun 30, 24 11.77 M
Decreased by -41.48%
-91.05 M
Decreased by -10.00%
Decreased by -773.45%
Decreased by -87.96%
Mar 31, 24 7.41 M
Decreased by -69.39%
-98.67 M
Decreased by -17.42%
Decreased by -1.33 K%
Decreased by -283.60%
Dec 31, 23 316.19 M
Increased by +1.48 K%
142.80 M
Increased by +472.36%
Increased by +45.16%
Increased by +123.60%
Sep 30, 23 17.19 M
Increased by +8.82%
-96.09 M
Increased by +12.31%
Decreased by -558.88%
Increased by +19.42%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY